secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001558370-24-016108
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NextCure FDA accepts IND for ADC LNCB74; Phase 1 trial to start
---------------------------------------------------------------

- FDA accepted IND for LNCB74, a B7-H4-targeting antibody-drug conjugate (ADC).
- Phase 1 trial will evaluate LNCB74 for multiple cancers.
- LNCB74 developed in partnership with LigaChem Biosciences under co-development agreement.
- NextCure CEO Michael Richman highlighted differentiation from other B7-H4 ADCs.
- IND acceptance allows NextCure to proceed with clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024016108/0001558370-24-016108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837024016108/nxtc-20241210x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-016108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer